Avenue Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview

Reuters

Mar 15

Avenue <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc <atxi.oq> expected to post a loss of 57 cents a share - Earnings Preview </atxi.oq>

Avenue Therapeutics Inc ATXI.OQ ATXI.O is expected to show no change in quarterly revenue when it reports results on March 17 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for Avenue Therapeutics Inc is for a loss of 57 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Avenue Therapeutics Inc is $8.00, above its last closing price of $0.77.

This summary was machine generated March 14 at 20:14 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2519033254"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2519033254\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2519033254?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-15 04:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2519033254","market":"us","top_or_hot":-1,"title":"Avenue Therapeutics Inc  expected to post a loss of 57 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Avenue <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <atxi.oq> expected to post a loss of 57 cents a share - Earnings Preview </atxi.oq></title></head><body><ul><li><p>Avenue Therapeutics Inc <span>ATXI.OQ</span> <span>ATXI.O</span> is expected to show no change in quarterly revenue when it reports  results on March 17 (estimated) for the period ending December 31 2024</p></li><li></li><li><p>LSEG's mean analyst estimate for Avenue Therapeutics Inc is for a loss of 57 cents per share. </p></li><li><p>The one available analyst rating on the shares is \"buy\".  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Avenue Therapeutics Inc is $8.00, above its last closing price of $0.77. </p></li></ul><p>This summary was machine generated March 14 at 20:14 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avenue Therapeutics Inc  expected to post a loss of 57 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvenue Therapeutics Inc  expected to post a loss of 57 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-15 04:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Avenue <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <atxi.oq> expected to post a loss of 57 cents a share - Earnings Preview </atxi.oq></title></head><body><ul><li><p>Avenue Therapeutics Inc <span>ATXI.OQ</span> <span>ATXI.O</span> is expected to show no change in quarterly revenue when it reports  results on March 17 (estimated) for the period ending December 31 2024</p></li><li></li><li><p>LSEG's mean analyst estimate for Avenue Therapeutics Inc is for a loss of 57 cents per share. </p></li><li><p>The one available analyst rating on the shares is \"buy\".  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Avenue Therapeutics Inc is $8.00, above its last closing price of $0.77. </p></li></ul><p>This summary was machine generated March 14 at 20:14 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FBIO","symbol_name":"Fortress Biotech Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL8N3PX21M:1","article_id":"2519033254","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2519033254","pubTimestamp":1741983245,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Avenue Therapeutics Inc  expected to post a loss of57cents a share - Earnings Preview Avenue Therapeutics Inc ATXI.OQ ATXI.O is expected to show no change in quarterly revenue when it reports  results","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"FBIO":"Fortress Biotech Inc.","ATXI":"Avenue Therapeutics, Inc."},"translate_title":"Avenue Therapeutics Inc预计每股亏损57美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FBIO":0.9,"ATXI":0.9},"content_text":"Avenue Therapeutics Inc  expected to post a loss of 57 cents a share - Earnings Preview Avenue Therapeutics Inc ATXI.OQ ATXI.O is expected to show no change in quarterly revenue when it reports  results on March 17 (estimated) for the period ending December 31 2024LSEG's mean analyst estimate for Avenue Therapeutics Inc is for a loss of 57 cents per share. The one available analyst rating on the shares is \"buy\".  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Avenue Therapeutics Inc is $8.00, above its last closing price of $0.77. This summary was machine generated March 14 at 20:14 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}